trial safety

Biotech

Ultragenyx granted go-ahead to up doses for Angelman therapy

Ultragenyx and partner GeneTx have been given the go-ahead to up the dose in a phase 1/2 Angelman syndrome trial of antisense treatment GTX-102.
Annalee Armstrong Jan 5, 2022 11:11am

Takeda stops narcolepsy clinical trials because of safety signal

Oct 6, 2021 4:45am

Acorda dumps $363M Parkinson’s drug after patient deaths

Nov 20, 2017 8:34am

Theravance COPD drug clears safety study, setting up NDA

Jul 20, 2017 6:44am

Juno ditches lead CAR-T program following patient deaths

Mar 2, 2017 4:03am

EMA updates first-in-human trial guidance

Nov 16, 2016 12:10pm